clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Granuloma, Plasma Cell D006104 1 associated lipids
Epilepsy, Partial, Motor D020938 1 associated lipids
Cutaneous Fistula D017577 1 associated lipids
Kleine-Levin Syndrome D017593 1 associated lipids
Encephalomyelitis, Acute Disseminated D004673 1 associated lipids
Empyema, Tuberculous D004654 1 associated lipids
Tuberculosis, Ocular D014392 1 associated lipids
Immune Reconstitution Inflammatory Syndrome D054019 1 associated lipids
Serositis D012700 1 associated lipids
Euthyroid Sick Syndromes D005067 1 associated lipids
Glossitis, Benign Migratory D005929 1 associated lipids
Parotid Diseases D010305 1 associated lipids
Extensively Drug-Resistant Tuberculosis D054908 1 associated lipids
Sacroiliitis D058566 1 associated lipids
Achlorhydria D000126 1 associated lipids
Upper Extremity Deep Vein Thrombosis D056824 1 associated lipids
Pseudomyxoma Peritonei D011553 1 associated lipids
Eye Infections D015817 1 associated lipids
Buruli Ulcer D054312 1 associated lipids
Gastritis, Hypertrophic D005758 1 associated lipids
Tuberculosis, Spinal D014399 1 associated lipids
Hypoproteinemia D007019 1 associated lipids
Myxoma D009232 1 associated lipids
Diphtheria D004165 2 associated lipids
Soft Tissue Infections D018461 2 associated lipids
Empyema, Pleural D016724 2 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Mastoiditis D008417 2 associated lipids
Periodontal Abscess D010508 2 associated lipids
Duodenogastric Reflux D004383 2 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Iritis D007500 2 associated lipids
Parotid Neoplasms D010307 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Monoclonal Gammopathy of Undetermined Significance D008998 2 associated lipids
IgA Deficiency D017098 2 associated lipids
Eye Injuries, Penetrating D015807 2 associated lipids
Chlamydial Pneumonia D061387 2 associated lipids
Leprosy, Lepromatous D015440 2 associated lipids
Discitis D015299 2 associated lipids
Iris Diseases D007499 2 associated lipids
Angiomatosis, Bacillary D016917 2 associated lipids
Tuberculosis, Avian D014379 2 associated lipids
Immunoproliferative Small Intestinal Disease D007161 2 associated lipids
Tooth, Nonvital D019553 2 associated lipids
Cardiovascular Abnormalities D018376 2 associated lipids
Hyperemesis Gravidarum D006939 2 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Leprosy, Paucibacillary D056005 2 associated lipids
Typhoid Fever D014435 2 associated lipids
Giardiasis D005873 3 associated lipids
Central Nervous System Protozoal Infections D020808 3 associated lipids
Eye Infections, Bacterial D015818 3 associated lipids
Conjunctival Neoplasms D003230 3 associated lipids
Empyema D004653 3 associated lipids
alpha 1-Antitrypsin Deficiency D019896 3 associated lipids
Tenosynovitis D013717 3 associated lipids
Pityriasis Rosea D017515 3 associated lipids
Pleuropneumonia D011001 3 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Ureteral Diseases D014515 3 associated lipids
Sporotrichosis D013174 3 associated lipids
Ecchymosis D004438 3 associated lipids
Hernia, Hiatal D006551 3 associated lipids
Fusobacterium Infections D005674 3 associated lipids
Conjunctivitis, Bacterial D003234 3 associated lipids
Keratoconjunctivitis D007637 3 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Bartonella Infections D001474 3 associated lipids
Paronychia D010304 3 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Scrub Typhus D012612 3 associated lipids
Fractures, Open D005597 3 associated lipids
Barrett Esophagus D001471 3 associated lipids
Cysts D003560 4 associated lipids
Duodenitis D004382 4 associated lipids
Gastritis, Atrophic D005757 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Esophagitis, Peptic D004942 4 associated lipids
Foot Diseases D005534 4 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Ergotism D004881 4 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Peptic Ulcer Hemorrhage D010438 4 associated lipids
Dermatitis, Phototoxic D017484 4 associated lipids
Pleural Diseases D010995 4 associated lipids
Rodent Diseases D012376 4 associated lipids
Parotitis D010309 4 associated lipids
Psittacosis D009956 4 associated lipids
Prurigo D011536 4 associated lipids
Confusion D003221 4 associated lipids
Lymphangitis D008205 4 associated lipids
Mycetoma D008271 4 associated lipids
Legionnaires' Disease D007877 4 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Hand Dermatoses D006229 5 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Liu KS et al. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. 2014 Gut pmid:24295850
Miwa S et al. Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study. 2014 Ann Am Thorac Soc pmid:24298907
Saadat A et al. The formulation, chemical and physical characterisation of clarithromycin-based macrolide solution pressurised metered dose inhaler. 2014 J. Pharm. Pharmacol. pmid:24329164
Rajput P et al. Bifunctional capsular dosage form: novel fanicular cylindrical gastroretentive system of clarithromycin and immediate release granules of ranitidine HCl for simultaneous delivery. 2014 Int J Pharm pmid:24309435
Katayama M et al. Preliminary study of effects of multiple oral dosing of clarithromycin on the pharmacokinetics of cyclosporine in dogs. 2014 J. Vet. Med. Sci. pmid:24189617
Papastergiou V et al. Current and future insights in H. pylori eradication regimens: the need of tailoring therapy. 2014 Curr. Pharm. Des. pmid:24180408
Tan X and Song Z Human saliva-based quantitative monitoring of clarithromycin by flow injection chemiluminescence analysis: a pharmacokinetic study. 2014 Appl. Biochem. Biotechnol. pmid:24166104
Kakuda TN et al. Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies. 2014 J. Antimicrob. Chemother. pmid:24155058
Seung KJ et al. Salvage therapy for multidrug-resistant tuberculosis. 2014 Clin. Microbiol. Infect. pmid:23991934
Kathariya R et al. Evaluation of subgingivally delivered 0.5% clarithromycin as an adjunct to nonsurgical mechanotherapy in the management of chronic periodontitis: a short-term double blinded randomized control trial. 2014 J Investig Clin Dent pmid:23097216
Shahbazi Niaz M et al. Investigation into physical-chemical variables affecting the manufacture and dissolution of wet-milled clarithromycin nanoparticles. 2014 Pharm Dev Technol pmid:24093825
Maev IV et al. [Eradication therapy for Helicobacter pylori infection: review of world trends]. 2014 Ter. Arkh. pmid:24779078
Katagiri S et al. [Case report; Disseminated Mycobacterium abscessus infection with hemophagocytic syndrome during treatment of chronic lymphocytic leukemia]. 2014 Nippon Naika Gakkai Zasshi pmid:24796145
Kato M [Expanded indication of National Health Insurance for H. pylori associated gastritis]. 2014 Nippon Rinsho pmid:24912302
Bjerre M et al. Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: the CLARICOR trial. 2014 Scand. J. Clin. Lab. Invest. pmid:25026506
Trotti LM et al. Improvement in daytime sleepiness with clarithromycin in patients with GABA-related hypersomnia: Clinical experience. 2014 J. Psychopharmacol. (Oxford) pmid:24306133
Noh TK et al. Infection with Mycobacterium fortuitum during acupoint embedding therapy. 2014 J. Am. Acad. Dermatol. pmid:24831334
Zhao Y and Hu ZY Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate. 2014 Br. J. Pharmacol. pmid:24283665
Loreto ES et al. New insights into the in vitro susceptibility of Pythium insidiosum. 2014 Antimicrob. Agents Chemother. pmid:25223997
Harvey E and Varatharaj A Round pneumonia. 2014 QJM pmid:23708793
Tsovolou EC et al. Effect of clarithromycin in experimental empyema by multidrug-resistant Pseudomonas aeruginosa. 2014 APMIS pmid:23656439
Altman E et al. Lipopolysaccharide glycotyping of clarithromycin-resistant and clarithromycin-susceptible Canadian isolates of Helicobacter pylori. 2014 Can. J. Microbiol. pmid:24392924
Kim SY et al. Changes in serum immunomolecules during antibiotic therapy for Mycobacterium avium complex lung disease. 2014 Clin. Exp. Immunol. pmid:24354934
De Francesco V et al. Change of point mutations in Helicobacter pylori rRNA associated with clarithromycin resistance in Italy. 2014 J. Med. Microbiol. pmid:24344205
Yamada K et al. Azithromycin inhibits MUC5AC induction via multidrug-resistant Acinetobacter baumannii in human airway epithelial cells. 2014 Pulm Pharmacol Ther pmid:24910464
Lee JY et al. Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. 2014 Dig. Dis. Sci. pmid:24599773
Zhao HM et al. [Clinical effect of triple therapy combined with Saccharomyces boulardii in the treatment of Helicobacter pylori infection in children]. 2014 Zhongguo Dang Dai Er Ke Za Zhi pmid:24661511
Oğuz M and Mihçiokur H Environmental risk assessment of selected pharmaceuticals in Turkey. 2014 Environ. Toxicol. Pharmacol. pmid:24929476
Gisbert JP et al. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection. 2014 Dig. Dis. Sci. pmid:24126798
Tranos P et al. Bilateral diffuse iris atrophy after the use of oral clarithromycin. 2014 Cutan Ocul Toxicol pmid:23763291
Kuroda H et al. [Three cases of lenalidomide-resistant IgA myeloma for which a response was regained after the addition of clarithromycin]. 2014 Gan To Kagaku Ryoho pmid:25248908
Bouricha M et al. Mycobacterium marinum infection following contact with reptiles: vivarium granuloma. 2014 Int. J. Infect. Dis. pmid:24530276
Peedikayil MC et al. Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials. 2014 PLoS ONE pmid:24465624
Yoshida N et al. A cross-sectional investigation of the quality of selected medicines in Cambodia in 2010. 2014 BMC Pharmacol Toxicol pmid:24593851
Vu DH et al. Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC-MS/MS. 2014 Talanta pmid:24607103
Zaiem A et al. Clarithromycin induced psoriasis in a 37-year old man. 2014 Curr Drug Saf pmid:24410388
Methaneethorn J et al. A pharmacokinetic drug-drug interaction model of simvastatin and clarithromycin in humans. 2014 Conf Proc IEEE Eng Med Biol Soc pmid:25571290
El-Garem Y et al. Seminal Helicobacter pylori treatment improves sperm motility in infertile asthenozoospermic men. 2014 Urology pmid:25432826
Kim SY et al. [Ten day concomitant therapy is superior to ten day sequential therapy for Helicobacter pylori eradication]. 2014 Korean J Gastroenterol pmid:25420735
Mustafa G and Necati B Clarithromycin-associated rhabdomyolysis in an infant. 2014 J Clin Rheumatol pmid:25417692
Komiya K et al. Long-term, low-dose erythromycin monotherapy for Mycobacterium avium complex lung disease: a propensity score analysis. 2014 Int. J. Antimicrob. Agents pmid:24948577
Ghrew MH et al. Successful renal transplant in patient with controlled pulmonary non-tuberculous mycobacterium infection. 2014 Libyan J Med pmid:25249307
Yoon KH et al. Clarithromycin-based standard triple therapy can still be effective for Helicobacter pylori eradication in some parts of the Korea. 2014 J. Korean Med. Sci. pmid:25246742
Matongo F and Nwodo UU In vitro assessment of Helicobacter pylori ureases inhibition by honey fractions. 2014 Arch. Med. Res. pmid:25240315
Martos M et al. Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions. 2014 Eur J Gastroenterol Hepatol pmid:25229983
Veraldi S et al. Treatment of sporotrichoid fish tank granuloma with pulsed clarithromycin. 2014 Dermatology (Basel) pmid:25228273
Phillips RO et al. Reply to "compliance with antimicrobial therapy for buruli ulcer". 2014 Antimicrob. Agents Chemother. pmid:25225343
Klis S et al. Compliance with antimicrobial therapy for buruli ulcer. 2014 Antimicrob. Agents Chemother. pmid:25225342
Park CS et al. Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance. 2014 Am. J. Gastroenterol. pmid:25091062
Cicek-Senturk G et al. Acute mercury poisoning presenting as fever of unknown origin in an adult woman: a case report. 2014 J Med Case Rep pmid:25084829
Bilgin M et al. Acute coronary syndrome secondary to clarithromycin: the first case and review of the literature. 2014 Turk Kardiyol Dern Ars pmid:25080953
Hsu PI et al. Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. 2014 Antimicrob. Agents Chemother. pmid:25070099
Patel SK et al. Helicobacter pylori is not eradicated after triple therapy: a nested PCR based study. 2014 Biomed Res Int pmid:25054141
Elkhatib W and Noreddin A Efficacy of ciprofloxacin-clarithromycin combination against drug-resistant Pseudomonas aeruginosa mature biofilm using in vitro experimental model. 2014 Microb. Drug Resist. pmid:25050970
Ohe M and Bohgaki T Successful treatment with clarithromycin for patients with polymyalgia rheumatica. 2014 Korean J. Intern. Med. pmid:25045305
Martin JH and Coombes I Mortality from common drug interactions systems, knowledge and clinical reasoning to optimise prescribing. 2014 Intern Med J pmid:25041768
Dalbøge CS et al. Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis. 2014 J. Cyst. Fibros. pmid:24035278
Philips RC et al. Mycobacterium fortuitum infection arising in a new tattoo. 2014 Dermatol. Online J. pmid:24945647
Klesiewicz K et al. PCR-RFLP detection of point mutations A2143G and A2142G in 23S rRNA gene conferring resistance to clarithromycin in Helicobacter pylori strains. 2014 Acta Biochim. Pol. pmid:24927236
Sugimoto M and Furuta T Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. 2014 World J. Gastroenterol. pmid:24914361
Heo J and Jeon SW Optimal treatment strategy for Helicobacter pylori: era of antibiotic resistance. 2014 World J. Gastroenterol. pmid:24914324
Glatz M and Muellegger RR Drug-associated aquagenic wrinkling of the palms in an atopic male patient. 2014 BMJ Case Rep pmid:24903725
DiCicco M et al. In vitro synergism of fosfomycin and clarithromycin antimicrobials against methicillin-resistant Staphylococcus pseudintermedius. 2014 BMC Microbiol. pmid:24886369
Noonan KA et al. Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma. 2014 Cancer Immunol Res pmid:24878583
Gong EJ et al. Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change? 2014 J. Korean Med. Sci. pmid:24851029
Jeon HK and Kim GH Does standard triple therapy still have a role in first-line Helicobacter pylori eradication in Korea? 2014 J. Korean Med. Sci. pmid:24851014
Graham DY et al. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. 2014 Clin. Gastroenterol. Hepatol. pmid:23751282
Jarand J and Field SK Embrace simplicity when treating lady windermere. 2014 Chest pmid:25091749
Khalili N Sunny hypomania associated with clarithromycin: a case report. 2014 J Clin Psychopharmacol pmid:24717249
Onyekwere CA et al. Rabeprazole, clarithromycin, and amoxicillin Helicobacter pylori eradication therapy: report of an efficacy study. 2014 World J. Gastroenterol. pmid:24707145
Wu JY et al. Detection of genotypic clarithromycin-resistant Helicobacter pylori by string tests. 2014 World J. Gastroenterol. pmid:24695835
Sugimoto M et al. Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion. 2014 Helicobacter pmid:24690010
Liu KY et al. Efficacy and pharmacological mechanism of pronase-enhanced low-dose antibiotics for Helicobacter pylori eradication. 2014 Antimicrob. Agents Chemother. pmid:24687504
Ikawa K et al. Pharmacokinetic modelling of serum and bronchial concentrations for clarithromycin and telithromycin, and site-specific pharmacodynamic simulation for their dosages. 2014 J Clin Pharm Ther pmid:24661290
Varvyanskaya A and Lopatin A Efficacy of long-term low-dose macrolide therapy in preventing early recurrence of nasal polyps after endoscopic sinus surgery. 2014 Int Forum Allergy Rhinol pmid:24659566
Lee SH et al. Detection and assessment of clarithromycin inducible resistant strains among Korean Mycobacterium abscessus clinical strains: PCR methods. 2014 J. Clin. Lab. Anal. pmid:24652818
Binh TT et al. Discovery of novel mutations for clarithromycin resistance in Helicobacter pylori by using next-generation sequencing. 2014 J. Antimicrob. Chemother. pmid:24648504
Karaolia P et al. Reduction of clarithromycin and sulfamethoxazole-resistant Enterococcus by pilot-scale solar-driven Fenton oxidation. 2014 Sci. Total Environ. pmid:24012892
Tursi A et al. Decreasing efficacy of the standard seven-day triple therapy containing amoxycillin and clarithromycin in curing Helicobacter pylori infection in clinical setting in Italy: a 10-year follow-up study. 2014 Panminerva Med pmid:24637473
Wei Z et al. Rome III criteria cannot distinguish patients with chronic gastritis from those functional dyspepsia patients. 2014 Helicobacter pmid:24617669
Rizzo A et al. Antimicrobial effect of natural polyphenols with or without antibiotics on Chlamydia pneumoniae infection in vitro. 2014 Microb. Drug Resist. pmid:23952319
Wu JY et al. Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate. 2014 Helicobacter pmid:24612093
Settin A et al. Cure rate of Helicobacter pylori infection in Egyptian children related to CYP2C19 gene polymorphism. 2014 Indian J Gastroenterol pmid:24610583
Zhang J et al. Ocular penetration and pharmacokinetics of topical clarithromycin eye drops to rabbits. 2014 J Ocul Pharmacol Ther pmid:24199739
Ali Habib HS et al. Effect of sequential versus standard Helicobacter pylori eradication therapy on the associated iron deficiency anemia in children. 2013 Sep-Oct Indian J Pharmacol pmid:24130381
Mégraud F Current recommendations for Helicobacter pylori therapies in a world of evolving resistance. 2013 Nov-Dec Gut Microbes pmid:23929066
Suzaki I et al. Enhancement of thioredoxin production from nasal epithelial cells by the macrolide antibiotic, clarithromycin in vitro. 2013 May-Jun In Vivo pmid:23606690
Dajani AI et al. Do probiotics improve eradication response to Helicobacter pylori on standard triple or sequential therapy? 2013 May-Jun Saudi J Gastroenterol pmid:23680708
Petitto J et al. Successful clarithromycin desensitization in a macrolide-sensitive pediatric patient. 2013 May-Jun J Allergy Clin Immunol Pract pmid:24565493
Cottle LE et al. A multinational outbreak of histoplasmosis following a biology field trip in the Ugandan rainforest. 2013 Mar-Apr J Travel Med pmid:23464714
Molina-Infante J and Gisbert JP [Update on the efficacy of triple therapy for Helicobacter pylori infection and clarithromycin resistance rates in Spain (2007-2012)]. 2013 Jun-Jul Gastroenterol Hepatol pmid:23623461
Razafimahefa SH et al. [Helicobacter pylori: what eradication regimen in a tropical area after the failure of two separate lines of eradication including metronidazole and clarithromycin?]. 2013 Jan-Mar Med Sante Trop pmid:23360589
Mandras N et al. Antibacterial efficacy and drug-induced tooth discolouration of antibiotic combinations for endodontic regenerative procedures. 2013 Apr-Jun Int J Immunopathol Pharmacol pmid:23755774
Ma Y et al. Characteristics and evaluation of an injectable clarithromycin lipid-based complex in vitro and in vivo. 2013 Drug Deliv pmid:24032596
Khamraev AA et al. [State of mucosal barrier of the stomach after Helicobacter pylori eradication and ulcer healing in patients with duodenal ulcer disease]. 2013 Eksp Klin Gastroenterol pmid:24933985
Lee G et al. Nodular bronchiectatic Mycobacterium avium complex pulmonary disease. Natural course on serial computed tomographic scans. 2013 Ann Am Thorac Soc pmid:23952847
Serelis J et al. Granulomatous infection of the hand and wrist due to Azospirillum spp. 2013 Diagn. Microbiol. Infect. Dis. pmid:23685031
Shinde DD et al. Different effects of clopidogrel and clarithromycin on the enantioselective pharmacokinetics of sibutramine and its active metabolites in healthy subjects. 2013 J Clin Pharmacol pmid:23381968
Xiong LJ et al. Detection of clarithromycin-resistant Helicobacter pylori by stool PCR in children: a comprehensive review of literature. 2013 Helicobacter pmid:23067446
Kwon HJ et al. Life-threatening scrub typhus with hemophagocytosis and acute respiratory distress syndrome in an infant. 2013 J. Trop. Pediatr. pmid:22735791